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The mammalian brain is anatomically and functionally complex, and prone to diverse forms
of injury and neuropathology. Scientists have long strived to develop cell replacement
therapies to repair damaged and diseased nervous tissue. However, this goal has
remained unrealized for various reasons, including nascent knowledge of neuronal
development, the inability to track and manipulate transplanted cells within complex
neuronal networks, and host graft rejection. Recent advances in embryonic stem cell
(ESC) and induced pluripotent stem cell (iPSC) technology, alongside novel genetic
strategies to mark and manipulate stem cell-derived neurons, now provide unprecedented
opportunities to investigate complex neuronal circuits in both healthy and diseased brains.
Here, we review current technologies aimed at generating and manipulating neurons
derived from ESCs and iPSCs toward investigation and manipulation of complex neuronal
circuits, ultimately leading to the design and development of novel cell-based therapeutic
approaches.
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INTRODUCTION
Within the mammalian nervous system, billions of neurons are
intricately interconnected via trillions of synapses. From this
complex network of synaptic connectivity, specialized neural cir-
cuits emerge, forming the foundation for diverse physiological
processes and behaviors. Due to the sheer complexity and het-
erogeneity of the cell and tissue types that contribute to neural
circuits, the brain is prone to an array of developmental and neu-
rodegenerative diseases, ranging from epilepsy (Noebels et al.,
2012; Pun et al., 2012), mental illness (Liemburg et al., 2012a,b),
Alzheimer’s disease (Cao et al., 2012; Grienberger et al., 2012),
Parkinson’s disease (Armstrong et al., 2002; Rochester et al.,
2012), and Huntington’s disease (Mazzocchi-Jones et al., 2009;
Niclis et al., 2009). Although highly heterogeneous in presen-
tation, etiology, and affected cell populations, neurological dis-
orders fundamentally involve the loss of proper circuit function
(Figure 1) (Miller et al., 2011; Noutel et al., 2011; Ramamoorthi
and Lin, 2011; Wang et al., 2011; Wesson et al., 2011; Ghiglieri
et al., 2012). In recent times, pharmacological interventions have
shown therapeutic promise toward the treatment of many neu-
rological disorders (Kraft et al., 2009; Ballatore et al., 2012; Das
et al., 2012; Fridhandler et al., 2012; Pedersen et al., 2012; Weaver
et al., 2012). For example, several forms of epilepsy can be
well controlled with pharmacology. Yet, in cases of severe neu-
rodegenerative disorders, drug therapy has shown more variable
results. This variability is compounded by the fact that medica-
tions are often initiated at late stages of disease when symptoms
become clinically evident, providing limited, if any, symptomatic
relief. Even in cases with promising drug therapy, one major
limitation is that patients may become desensitized and thus
require increasingly higher doses of medication until they reach
the point of tolerance (Gancher et al., 1996). Further, even if a
patient’s symptoms are controlled with medication, prohibitive
side effects may restrict the utility of pharmacological therapy.
Finding the right therapeutic approach is therefore a challenge
for many patients, especially when such limits of drug therapy
have been reached. Neurosurgical options, including deep brain
stimulation implants in Parkinson’s disease patients, are increas-
ingly offered to those whose symptoms are pharmacologically
non-responsive, to promote activity of remaining functional neu-
ronal tissue. However, these approaches can be accompanied
by the general risks of invasive procedures, and their mecha-
nisms of action remain to be characterized. In the emerging era
of stem cell therapy, much hope lies in developing a less inva-
sive, cell-based therapy that offers the unique ability to replace
dysfunctional, damaged, or lost neurons. The promise of cura-
tive approaches for such progressive and devastating conditions
as Huntington’s disease, Alzheimer’s disease, Parkinson’s disease,
and Amyotrophic Lateral Sclerosis has lured many patients to
undergo alleged stem cell transplants from a range of medical
providers, offering these procedures in absence of a critical mass
of controlled clinical trials and detailed understanding of the
mechanisms of a cell-based therapeutic approach to neurodegen-
erative diseases.
Recent efforts have focused on developing mechanistic insight
into cell-based therapies (Alvarez Dolado and Broccoli, 2011;
Dyson and Barker, 2011; Freed et al., 2011; Chen and Blurton-
Jones, 2012; Kauhausen et al., 2012; Moviglia et al., 2012).
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FIGURE 1 | Functional circuit formation stems from precise coordination
between diverse neuronal and glial subtypes. In the mammalian brain,
neurons are connected to each other via synapses, forming complex
neuronal circuits. The development and maturation of these circuits requires
precise coordination between heterogeneous cell populations consisting of
diverse neuron and glial subtypes. During development, neural progenitor
cells give rise to neurons and glia. In neurodevelopmental and
neurodegenerative disorders, proper neuron and glial interactions do not
occur due to cellular malfunction. This malfunction impairs functional circuit
formation and leads to circuit dysfunction. Impaired neuronal circuits are
implicated in a wide variety of disorders such as epilepsy, Alzheimer’s,
Parkinson’s, and Huntington’s diseases.
Cellular approaches aimed at understanding and treating neu-
rological diseases have ranged from the direct transplantation
of embryonic, neuronal, and fetal stem cells (Bjorklund et al.,
2002; Erdo et al., 2004; Hattiangady et al., 2007; Kauhausen et al.,
2012; Moon et al., 2012) in rodent models, to the in vitro genera-
tion and investigation of induced pluripotent stem cells (iPSCs)
and induced neural stem cells (iNSCs) from affected patients’
tissues (Takahashi and Yamanaka, 2006; Takahashi et al., 2007;
Han et al., 2012; Ring et al., 2012; Thier et al., 2012). Although
induced stem cells have yielded valuable in vitro models of sev-
eral neurological disorders (Camnasio et al., 2012; Israel et al.,
2012; Ooi et al., 2012; Yagi et al., 2012), numerous studies have
identified major challenges that have hindered transplantation
efforts. Notable examples include teratoma formation (Bjorklund
et al., 2002; Seminatore et al., 2010; Cunningham et al., 2012;
Garcia et al., 2012), graft rejection (Krystkowiak et al., 2007), neu-
ronal death (Nolte et al., 2008; Wang et al., 2012), and improper
integration into pre-existing brain circuits (Kelly et al., 2007;
Wang et al., 2012). In order to begin to harness the potential of
stem cell therapy toward the treatment of neurological disorders,
these issues must be addressed. Here, we review current litera-
ture regarding the generation of neurons from different stem cell
populations and discuss their potential use for both in vitro stud-
ies and in vivo transplantation. We further provide an overview
of current strategies to mark and manipulate neuronal activity
in intact brain tissues, and discuss the interface between these
genetic and cellular technologies to investigate circuit formation
and function. Finally, we conclude by exploring the future of ther-
apeutic interventions for damaged and diseased nervous systems
using genetically modified stem cell-derived neurons.
GENERATING NEURONS FROM EMBRYONIC STEM CELLS
In the hopes of curing or providing therapeutic measures for
damaged and diseased nervous tissue, significant interest has
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been placed in developing stem cell-based therapies for common
neurological disorders (Babaei et al., 2012; Chen and Blurton-
Jones, 2012; Lescaudron et al., 2012; Moon et al., 2012). Early
attempts in animal models were aimed at transplanting pure pop-
ulations of ESCs directly into damaged or diseased brain tissue
(Deacon et al., 1998; Bjorklund et al., 2002; Erdo et al., 2004),
with the intent of providing a source of renewable cells capa-
ble of functionally integrating into existing circuits. This notion
was supported by optimism that naive stem cells would respond
to cues from the surrounding tissue and ultimately differentiate
and function as mature neurons with appropriate synaptic con-
nections. However, many obstacles have hindered this approach.
First, transplantation of pluripotent stem cells into the brains
of animals can lead to restrictively high incidence of teratomas
(Bjorklund et al., 2002; Erdo et al., 2004); in some cases, 25%
or more of all grafts can result in undifferentiated brain tumors
(Garcia et al., 2012). In attempt to avoid teratoma formation,
efforts next turned toward transplantation of adult and fetal neu-
ral stem cells (NSCs) (Fainstein et al., 2012; Moon et al., 2012;
Muneton-Gomez et al., 2012). With putative lineage restriction,
NSCs were considered to have potential as a renewable source
of neuronal and glial subtypes, without the attendant risk of
teratoma formation. However, in lieu of generalized teratoma for-
mation, transplanted NSCs have been observed to produce neural
lineage-restricted brain tumors, such as medulloblastomas and
gliomas in animal models (Swartling et al., 2012). Alongside these
challenges other obstacles have surfaced, including graft rejection
(Capetian et al., 2011; Chen et al., 2011). While cell transplan-
tation can be straightforward, the procedure may activate host
immune responses, which can result in rejection of transplanted
cells prior to circuit integration. To circumvent this, immunosup-
pressive drugs are required during and after cell transplantation
(Leveque et al., 2011; Hovakimyan et al., 2012). Unfortunately,
immunosuppressants do not completely eliminate graft rejection,
and they invite susceptibility to various types of opportunistic
infections (Kasper et al., 2011; Pustavoitau et al., 2011; Dhar et al.,
2012).
Significant efforts have since been made to develop in vitro dif-
ferentiation protocols to program stem cells into distinct neuronal
lineages, thus avoiding unrestricted clonal expansion and tumor
formation prior to terminal differentiation (Caiazzo et al., 2011;
Chung et al., 2011; Jing et al., 2011; Juliandi et al., 2012; Kirkeby
et al., 2012). It is now possible to routinely generate high num-
bers of ESC-derived neurons of various subtypes in vitro (Bibel
et al., 2007; Parsons et al., 2011; Garcia et al., 2012; Kirkeby et al.,
2012; Moon et al., 2012; Salti et al., 2012). Molecularmarker anal-
ysis and electrophysiological characterizations have demonstrated
that these neurons appropriately differentiate in vitro and exhibit
patterns of action potentials and neurochemical profiles charac-
teristic of neurons found in intact brain tissue (Bissonnette et al.,
2011; Caiazzo et al., 2011; Cho et al., 2011; Garcia et al., 2012).
Using specialized protocols, heterogeneous populations of NSCs,
as well as GABAergic, glutamatergic, dopaminergic, and vari-
ous other neuronal and glial subpopulations can be obtained at
high quantities. Importantly, using these in vitro-generated neu-
ronal subpopulations, it is possible to specifically target affected
cell populations in diverse disease models. Furthermore, these
differentiated cellular subtypes provide a valuable resource for
in vitro studies. With renewable sources of diverse neuronal
lineages, numerous studies have implemented transplantation
methods to attempt treatment of specific neurological disor-
ders. In some cases, therapeutic effects have been observed (Song
et al., 2007; Chung et al., 2011; Kriks et al., 2011). For example,
improved behavioral outcomes in animal models of Parkinson’s
disease and other movement disorders have been observed fol-
lowing stem cell-based therapies (Song et al., 2007; Chung et al.,
2011; Kriks et al., 2011), and transplantation of GABAergic neu-
rons have shown modest decreases in seizure activity in epilepsy
models (Castillo et al., 2008; Maisano et al., 2009). However, it
remains unknown whether observed therapeutic effects are evi-
dence of functional restoration by engrafted cells or are the result
of stromal neuroprotective effects, including improved vascular-
ization and secretion of neurotrophic factors. Therefore, it has
become a priority to investigate the potential for transplanted
progenitor cells to properly differentiate, synaptically mature, and
appropriately integrate within functional neural circuits in vivo.
Toward this effort, numerous methodologies have emerged to
differentiate stem cells into neuronal lineages and genetically
engineer them to mark and manipulate their patterns of synaptic
connectivity (Figure 2).
GENERATING NEURAL STEM CELLS FROM SOMATIC CELL
TYPES
To circumvent host stem cell graft rejection, emphasis has been
placed on developing methods to genetically reprogram adult
somatic cells to a state of pluripotency, resembling embryonic
stem cells (ESCs). These iPSCs can be differentiated into neu-
ronal subtypes in vitro and autologously transplanted back into
the donor brain. Because these cells are patient-derived, they are
thought less likely to be rejected by the host immune system,
leading to improved graft survival. The first successful method of
cellular reprogramming published by Takahashi and Yamanaka,
demonstrated that somatic cells from both mice (Takahashi and
Yamanaka, 2006) and humans (Takahashi et al., 2007) can be
manipulated to adopt a pluripotent state. This discovery received
the Nobel Prize in Physiology orMedicine in 2012. Cellular repro-
gramming is accomplished by ectopic expression of transcription
factors in somatic cells. When cultured appropriately, these cells
further produce lineages derived from any of the three embry-
onic germ layers (Vierbuchen et al., 2010; Han et al., 2012; Ring
et al., 2012; Thier et al., 2012). Notably, these studies demon-
strate effective generation of ectodermal-like neuronal precursors
with capacity to mature into functional neurons capable of gen-
erating specific patterns of action potentials in vitro. Techniques
have since advanced to facilitate reprogramming from a vari-
ety of starting cell types, including fibroblasts (Pfisterer et al.,
2011; Ring et al., 2012), keratinocytes (Petit et al., 2012), and
blood cells (Ma et al., 2011). Additionally, methods have been
devised to bypass the pluripotent state, thereby directly gener-
ating iNSCs (Hanna et al., 2007; Denham and Dottori, 2011;
Pfisterer et al., 2011; Soldner et al., 2011; Yusa et al., 2011; Han
et al., 2012; Ring et al., 2012; Thier et al., 2012). Bypassing the
pluripotent state allows for direct generation of neuronal sub-
types, minimizing risk of teratoma formation. Reprogramming
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FIGURE 2 | Genetic manipulation of embryonic stem cell-derived
neurons. Human and mouse embryonic stem cells (ESCs) can be
routinely cultured in vitro. Through genetic manipulations, stem cells can
be endowed with structural reporters such as fluorescent markers,
activity reporters including transsynaptic tracing machinery and calcium
indicators, as well as functional enhancers such as light-responsive
proteins and exogenous ligand-activated ion channels. Upon neuron
subtype-specific differentiation, modified ESCs will give rise to
heterogeneous neuronal and glial subtypes. In vitro-generated neurons
can be transplanted into healthy and diseased brain tissue. With this
technology, it is possible to perform morphological analysis, transsynaptic
tracing, and activity measurements and manipulation of transplanted
neurons, allowing the functional investigation of neuronal circuit
integration in the brain.
technology thus provides an elegant means to generate rela-
tively inaccessible or growth-restricted cell lineages from readily
obtained tissue samples, with virtually unlimited potential for
both basic research and clinical application. One can perhaps
envision a near future where biomarkers are used to identify neu-
rological disease patients prior to symptom onset, and where the
patient’s own somatic cells can be used to validate and study these
disorders without having to obtain neural biopsies via invasive
measures.
However, similar to difficulties with ESC-derived neurons,
efficacy of induced stem cell transplants in animal models
can be complicated by tumorigenic transformation (Yamanaka,
2009; Fong et al., 2010) resulting from the genomic integra-
tion or sustained expression of reprogramming factors (Okita
et al., 2008). Thus, there remains a need for more “factor-free”
reprogramming technologies to eliminate oncogenic potential.
Moreover, although studies are now beginning to evaluate in vitro
connectivity of grafted neural cells with host tissue (Tonnesen
et al., 2011), the long-termmaintenance of these connections and
the survival potential for in vivo transplants remain unknown.
With the development of a more extensive genetic and biological
toolset, iNSC technology is poised to overcome such limitations.
Genetic manipulation and transplantation of stem cell-derived
neurons into live animals will provide a better understanding
of different measures of synaptic structure and/or function in
the intact brain. Detailed investigations of neuronal organization
promise to advance our working knowledge of circuit architec-
ture and operation in both healthy and diseased brain tissue with
ever-greater resolution.
VIRAL-BASED APPROACHES TO INVESTIGATE NEURONAL
CONNECTIVITY
In order to properly generate desired neuronal subtypes and tar-
get areas for transplantation studies, it is necessary to reveal the
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precise patterns of cellular connectivity in particular brain regions
and in disease models. Classical studies have applied anatomical
methods using histology, light microscopy, and ultrastructural
analysis to label and identify neurons that make synaptic con-
nections (Stevens et al., 1980; Anderson et al., 1994; Ahmed
et al., 1997; Briggman and Denk, 2006; Micheva and Smith,
2007). Structural studies provide great insight into synaptic
connectivity, but without additional functional analysis, these
connections should perhaps be considered “passive.” To further
characterize passive connectivity, a number of tracing methods
have been implemented, including fluorogold retrograde trac-
ers (Gomez-Nieto et al., 2008; Rossetti et al., 2012), biotinylated
dextrans (Shehab et al., 2005; Rossetti et al., 2012), wheat germ
agglutinin (Louis et al., 2010), cholera toxin conjugated dyes
(Angelucci et al., 1996; Miyashita and Rockland, 2007), fluores-
cent microspheres (Apps and Ruigrok, 2007; Neely et al., 2009),
and lipophilic dyes (Bruce et al., 1997; Makarenko et al., 2000).
However, a major limitation to these methods is the gradual
signal decline with distance or degree of labeled projections.
Additionally, indiscriminate cell-to-cell spread can occur between
contacting cells in close proximity, obscuring the interpretation of
functional connectivity. As such, these classical technologies label
connected neurons anatomically, but do not reveal true functional
connections.
To elucidate networks between synaptically-coupled partners
more precisely, novel technologies using neurotropic viruses have
been established (Callaway, 2008; Ugolini, 2010, 2011; Arenkiel,
2011; Arenkiel et al., 2011). Two prominent subtypes of viruses
used for transneuronal tracing include rabies virus (RV) and her-
pes virus (Callaway, 2008; Ugolini, 2010). Both infect cells via
retrograde particle transfer, allowing for the identification of neu-
rons presynaptic to an infected source cell. In order to determine
the precise identity of synaptic partners, fluorescent proteins
have been engineered into the herpes and rabies viral genomes
(Kuypers and Ugolini, 1990; Wickersham et al., 2007a; Callaway,
2008), allowing synaptically connected cells to be visualized via
detection of viral transfer using fluorescence microscopy. Because
these viral particles are self-replicating, their signal is sustained
over time and distance, and all synapses are labeled with sim-
ilar efficiency. The two most common herpes strains used for
viral tracing include herpes simplex virus 1 (HSV-1) (Lilley et al.,
2001) and pseudorabies virus (PRV) (Enquist, 2002). Both strains
are potent neuronal tracers and mark synaptically connected
neurons with very high efficiency. However, a major limitation
of the use of herpes virus for synaptic tracing studies is its
polysynaptic spread (Callaway, 2008; Ugolini, 2010). Herpes virus
moves across synapses very quickly, rapidly infecting brain tissue
and making it difficult to dissect precise synaptic connections.
Additionally, herpes virus integrates into cellular genomes and
promptly becomes toxic to the infected animal, leading to death
within days (Ugolini, 2010). To overcome these limitations, other
transsynaptic viral vectors have been engineered. Like HSV, RV
spreads to synaptically connected neurons in a retrograde man-
ner. But because its genome consists of negative strand RNA, RV
does not integrate into cellular DNA and is less toxic to infected
neurons (Callaway, 2008). Infected cells remain healthy for up to
two weeks, allowing for the functional investigation of synaptic
partners.
Wickersham et al. have demonstrated that genetically altered
RV can be used for precise identification of synaptic partners
(Wickersham et al., 2007a). To achieve this, the rabies glycopro-
tein G gene, which encodes the viral capsid and enables viral
assembly and spread is deleted and replaced with the gene for
enhanced green fluorescent protein (EGFP). These engineered
RV particles infect neurons with high efficiency and use the host
cellular machinery to replicate and produce high amounts of
EGFP, without generating infectious virions. Because the viral
genome is engineered without glycoprotein G, only primarily
infected neurons are labeled (Wickersham et al., 2007a). To opti-
mize engineered RV for transsynaptic circuit tracing,Wickersham
et al., “pseudotyped” the viral particles with the foreign coat pro-
tein EnvA from the avian sarcoma leukosis virus (Wickersham
et al., 2007b). EnvA recognizes the TVA receptor that is natu-
rally only found on cell membranes of certain avian species and
is not normally present on the mammalian neuronal membrane.
By introducing cDNA encoding both the rabies G glycopro-
tein and TVA receptor, together with a fluorescent marker such
as tdTomato for identification purposes, targeted neurons can
be infected by the pseudotyped RV, which also encodes EGFP.
Additionally, when exogenous glycoprotein G is provided in trans,
the virus is mobilized to replicate, self-assemble, and carry out a
single retrograde jump to its presynaptic inputs. Because presy-
naptic partners do not express glycoprotein G, and no further
glycoprotein G is provided, viral tracing comes to a halt, marking
monosynaptically connected input neurons (Wickersham et al.,
2007b). Such tracing methods have been extremely powerful to
deduce local patterns of neuronal connectivity (Arenkiel et al.,
2011; Miyamichi et al., 2011).
Recently, stable mouse ESC lines have been engineered to har-
bor transsynaptic tracing elements (glycoprotein G, TVA, and
a tdTomato reporter) (Garcia et al., 2012). These cells can be
differentiated with high efficiency into diverse neuronal lineages
as verified via molecular marker expression and electrophysiolog-
ical analysis. When introduced into slice cultures in vitro, or into
intact brain tissue in vivo, the transplanted cells can be identified
by fluorescent reporter expression and subsequently infected with
pseudotyped RV to act as source cells for circuit tracing studies
(Figure 3). In the past, studies with NSC transplants have used the
expression of fluorescent reporters (Chang et al., 2012; Steinbeck
et al., 2012), magnetic resonance imaging, positron emission
tomography (Daadi et al., 2009; Tang et al., 2011; Chang et al.,
2012), and phenotypic rescue (Yang et al., 2008; Nagai et al., 2010;
Chung et al., 2011; Zhu et al., 2011) to verify the integration of
stem cell-derived neurons into brain circuits. However, whether
transplanted cells forge functional connections within existing
circuitry has remained difficult to ascertain. Through new genetic
tracing technologies, it is now feasible to elucidate local networks
of synaptic connectivity and to determine the cast of presynaptic
contacts that form onto transplanted stem-cell derived neurons.
With the knowledge obtained from neuronal tracing studies in
healthy and diseased brains, combined with genetic strategies for
neuronal activity manipulations, it is possible to genetically target
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FIGURE 3 | In vivo circuit analysis with derived or reprogrammed
neurons harboring viral circuit tracing elements. Using neuron
subtype-specific differentiation or reprogramming protocols, a specialized
population of neural stem cells can be obtained in vitro. Electroporation
or stable transfection with a transsynaptic tracing vector provides the
rabies G coat protein and the TVA receptor, which are components of the
monosynaptic circuit tracing process. Incorporation of the viral tracing
vector into the stem cell genome transforms these cells into “source” cells
for circuit tracing. These cells can be implanted in vivo and identified by
expression of the tdTomato fluorescent reporter. After a defined time
period of maturation of the implanted cells, pseudotyped rabies virus is
injected. The virus specifically targets TVA-expressing source cells and
marks them with the EGFP fluorescent reporter. The source cells thus
fluorescence both red and green, indicated by a yellow color. The circuit
tracing system allows a single retrograde jump of virions carrying the EGFP
reporter from the source cell to presynaptic neurons. This identifies
synaptic connections and functional circuits formed by integrated neural
stem cells with high specificity.
healthy and diseased neuronal circuits for precise labeling and/or
control of neuronal firing (Figure 2).
GENETIC APPROACHES TO MANIPULATE NEURAL CIRCUIT
ACTIVITY
The desire to use cell-based therapeutic approaches toward the
treatment of damaged or diseased nervous tissue is rapidly gain-
ing popularity. However, prospects for these approaches depend
both on the ability to guide selective programs of neuronal dif-
ferentiation, and to engineer cells whose output can be precisely
controlled. In the adult brain, it has been established that diverse
forms of activity govern the integration and survival of new neu-
rons (Nilsson et al., 1999; van Praag et al., 1999; Rochefort et al.,
2002; Leuner et al., 2004; Rochefort and Lledo, 2005; Yamaguchi
and Mori, 2005). Through application of novel genetic tools, it is
now possible to artificially “induce” or “silence” activity in brain
circuits using light (Nagel et al., 2005; Arenkiel et al., 2007; Zhang
et al., 2007a,b; Chow et al., 2010; Deisseroth, 2010; Zhang et al.,
2010; Tonnesen et al., 2011; Madisen et al., 2012), or exogenous
chemical ligands (Tan et al., 2006; Lerchner et al., 2007; Arenkiel
et al., 2008; Conklin et al., 2008; Drenan et al., 2008; Wehr et al.,
2009). Furthermore, genetically encoded calcium indicators pro-
vide a method for functional readout in neurons (Pologruto et al.,
2004; Mao et al., 2008; Tian et al., 2009; Akerboom et al., 2012;
Chen et al., 2012). This capability is especially valuable for cell-
based circuit and tissue repair, where integration and functional
control may be desired. Early efforts toward manipulating neu-
ronal activity in select cell types have used exogenous ligands
not normally present in the brain (Arenkiel et al., 2008; Drenan
et al., 2008; Wulff and Arenkiel, 2012). Chemical genetic tech-
nologies have demonstrated both the activation (Arenkiel et al.,
2007; Conklin et al., 2008; Drenan et al., 2008) and silencing (Tan
et al., 2006; Lerchner et al., 2007; Wehr et al., 2009) of select neu-
ronal cell types in intact brain tissue both in vitro and in vivo. For
example, the transgenic overexpression of ligand-gated ion chan-
nels (LGIC) in neuronal subtypes allows cellular activation upon
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exogenous ligand administration (Drenan et al., 2008; Magnus
et al., 2011). Examples of chemical genetic tools for neuronal acti-
vation include expression of modified opiate receptors (Coward
et al., 1998), custom Gq-protein coupled receptors with high sen-
sitivity for synthetic ligands (DREADD hM3Dq) (Armbruster
et al., 2007), hyperdopaminergic activity via ectopic acetylcholine
receptor activation (Drenan et al., 2008), as well as expression
of the transient receptor potential cation channel subfamily V
member 1 (TRPV1), which is normally expressed in nociceptive
peripheral neurons and can be potently activated by administra-
tion of capsaicin (Arenkiel et al., 2008). Alongside this, several
chemical genetic tools have also been developed to artificially
silence neuronal activation, and include ectopic expression of a
glutamate-gated chloride channel (GluCl) from Caenorhabditis
elegans, which is activated by the antihelminthic drug ivermectin
(Slimko et al., 2002; Lerchner et al., 2007), Gi-coupled recep-
tors with high sentitivity for synthetic ligands (DREADD hM4Di)
(Arenkiel et al., 2007), as well as expression of the Drosophila
allatostatin receptor (AlstR) which induces Gi-coupled silenc-
ing in the presence of the insect peptide allatostatin (Birgul
et al., 1999). Using chemical genetics, it becomes possible to pre-
cisely control neuronal output with high specificity. However,
the use of exogenous ligands in living organisms poses several
challenges. For example, it is necessary to consider the intrinsic
properties of the ligand itself, as well as potential homeostatic
mechanisms present in living tissues. Notably, engineered lig-
ands must be inert and able to cross the blood-brain barrier.
Further, ligands should be non-toxic to the animal and rapidly
degraded in order to allow for precise time-dependent control
of neuronal manipulation. Because of the challenges posed by
chemical genetic technologies, researchers have also implemented
optical genetic methods for controlling neuronal activity with
light (Nagel et al., 2005; Arenkiel et al., 2007; Chow et al., 2010;
Deisseroth, 2010).
Optogenetic approaches allow for fast and precise control of
neuronal activity using light-activated ion channels via a spec-
trum of different wavelengths (Zhang et al., 2007a,b, 2010).
The most popular light-activated ion channels used for neu-
ronal depolarization are the channelrhodopsins, originally iden-
tified in the green algae Chlamydomonas reinhardtii (Nagel et al.,
2005; Deisseroth, 2010). In response to blue light (480 nm),
channelrhodopsin-2 (ChR2)-expressing neurons rapidly influx
cations, which depolarize the cell membrane, leading to firing
of action potentials. ChR2-assisted circuit mapping (CRACM)
has allowed precise dissection of neuronal circuits by stimulating
and activating ChR2-expressing neurons while recording electro-
physiological responses in postsynaptic neurons (Petreanu et al.,
2007). Alternatively, action potential inhibition can be achieved
via light-activated hyperpolarizing channels. This may be accom-
plished by either light-directed anion influx, or proton efflux.
Halorhodopsin (NpHR) is a light-driven chloride pump that
is activated with yellow-green light (570 nm) to drive chloride
ions into cells, whereas archaerhodopsin actively drives protons
out of the cell upon illumination with yellow-green light (Chow
et al., 2010; Madisen et al., 2012). In vitro differentiated neurons
harboring ChR2 and NpHR have recently revealed important
FIGURE 4 | Hopes for using induced neuronal stem cells for
regenerative medicine. Skin biopsies from patients with focal
neurological injury or neurodegenerative disease are a ready source
of fibroblasts. Using the approach of cellular reprogramming and
subsequent genetic manipulations, patient-derived fibroblasts can be
differentiated into induced neural stem cells (iNSCs) harboring functional
elements. Depending on the patient’s needs, iNSCs can be
differentiated in vitro into specialized neuronal subtypes. Patient-derived
neurons can then be transplanted by local injection into areas of
diseased or damaged brain tissue. Upon integration, these cells
regenerate parenchymal tissue, replacing dysfunctional cells and
ultimately supporting functional recovery.
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information regarding the functional integration of intrastriatal
grafts in a Parkinson’s disease model (Tonnesen et al., 2011).
Additionally, genetically encoded calcium indicators such as
GCaMP allow for functional readout of manipulated neurons
(Pologruto et al., 2004; Mao et al., 2008; Tian et al., 2009;
Akerboom et al., 2012; Chen et al., 2012). GCaMP is a modi-
fied GFP fused to calmodulin. Upon calcium influx, such as in
the case of depolarization, GCaMP undergoes a conformational
change, leading to increased fluorescence intensity. In the absence
of calcium influx, the GCaMP-expressing cells fluoresce dimly.
The emerging array of genetic tools for precise manipulation
of neuronal activity gives hope to transitioning stem cell therapy
from the conceptual to the clinical realm. For example, it may
soon be possible to generate NSCs expressing detectable markers
and/or activity-induced ion channels from patients with damaged
or diseased nervous tissue and transplant these cells back into the
affected patient (Figure 4). Such genetic strategies might enable
monitoring of the integration and survival of transplant-derived
neurons, and perhaps through controlled activity manipulations
result in symptomatic relief in select neurological disorders.
CONCLUDING REMARKS
Advances in stem cell research combined with powerful genetic
technologies now allow unprecedented levels of investigation and
manipulation of complex neuronal circuits. Previous efforts to
implement cell-based therapies have been hindered by tumori-
genesis, graft rejection, cell death, lack of circuit integration, and
the inability to follow grafted cells in vivo. Scientific advances are
beginning to tackle these challenges. Further, transsynaptic trac-
ing has enabled high resolution dissection of neuronal circuits,
which has begun to reveal insights into the molecular mecha-
nisms that guide synapse formation and circuit integration in
the living brain. Genetic approaches to manipulate neural circuit
activity have allowed for the selective “activation” and “silencing”
of discrete neuronal subtypes. This knowledge, combined with
the ability to generate high numbers of neurons in vitro, promises
to yield significant advances in cell therapy. In the future, it might
be possible to manipulate injured and/or diseased brain circuits
with artificially grafted cells, allowing for sustained symptomatic
relief in a range of neurological disorder and neuronal injury
models.
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